Bristol-Myers Squibb Posts Flat Full-Year 2025 Revenue Compared to 2024
Bristol-Myers Squibb reported flat full-year 2025 revenue, matching its 2024 top line with no year-over-year growth. The company provided no further breakdown of regional or product-line performance in the report.
1. Flat Full-Year Revenue
Bristol-Myers Squibb announced that its total revenue for full-year 2025 was unchanged from 2024, marking zero percent growth. Management attributed the performance to offsetting trends across its biopharma portfolio but did not disclose detailed segment or regional breakdowns.
Related News
GILD
Gilead Launches Five-Year WHO Collaboration with $9.2M Aid and 400,000 AmBisome Vials
GILD•
AMD
AMD Pledges $10B Taiwan Investment for 2.5D EFB Packaging and Ramps 2nm “Venice” CPUs
AMD•
NVDA
Nvidia posts $81.6bn Q1 revenue, raises dividend 25-fold and authorizes $80bn buyback
NVDA•
META
Manus Founders Seek $1B Raise to Unwind Meta's $2B AI Acquisition
META•
GS
Goldman Sachs to Lead $1.75 Trillion SpaceX IPO With $1.45B Bitcoin Disclosure
GS•
Sources
FB